Showing 3401-3410 of 5646 results for "".
- Commentary: Endothelial Cell Density After Iris-Fixated Phakic IOLhttps://modernod.com/news/endothelial-cell-density-after-iris-fixated-phakic-iol/2479908/There are three main types of phakic intraocular lenses (pIOL): those secured in the anterior chamber angle, those secured to the iris, and those placed between the crystalline lens and the iris. The latter two types are approved by the US Food and Drug Administration for use in the United States
- Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Publishedhttps://modernod.com/news/scientific-data-for-novel-adeno-associated-virus-gene-therapy-in-rhodopsin-mediated-autosomal-dominant-retinitis-pigmentosa-published/2479920/Ophthotech announced that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-a
- CDC Launches the Nation’s First Vision and Eye Health Surveillance Systemhttps://modernod.com/news/cdc-launches-the-nations-first-vision-and-eye-health-surveillance-system/2479924/The Centers for Disease Control and Prevention (CDC) has developed the nation’s first Vision and Eye Health Surveillance System (VEHSS). Launched in collaboration with the National Opinion Research Center (NORC), the VEHSS is designed to help health care professionals, researchers, policymakers,
- Roche’s Genentech Unit to Cut 223 Jobs in UShttps://modernod.com/news/roches-genentech-unit-to-cut-223-jobs-in-us/2479930/Roche’s Genentech unit plans to cut 223 jobs from its South San Francisco, California headquarters by the end of the year. The company, which disclosed the staff reductions in a Worker Adjustment and Retraining Notification (WARN) posted by the State of California’s Employment Develop
- Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMDhttps://modernod.com/news/regeneron-faces-delay-to-fda-approval-of-12-week-dosing-schedule-for-eylea-in-wet-amd/2479946/Regeneron announced that the FDA issued a complete response letter regarding a filing seeking approval of a 12-week dosing schedule for »Eylea (aflibercept) in patients wit
- Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates IOP Lowering and Patient Usabilityhttps://modernod.com/news/eyenovias-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates-iop-lowering-and-patient-usability/2479947/Eyenovia announced positive results of its EYN PG21 proof-of-concept study of microdose latanoprost for the lowering of IOP and patient usability. The EYN PG21 clinical study investigated the medication administration effectiveness and IOP lowering effect of
- Gene Mutation Found in Aqueous Humor May Detect Vitreoretinal Lymphomahttps://modernod.com/news/gene-mutation-found-in-aqueous-humor-may-detect-vitreoretinal-lymphoma/2479958/Ultrasensitive droplet digital polymerase chain reaction (ddPCR) is a potential new biopsy tool to diagnose and monitor vitreoretinal lymphoma (VRL), new research from the Netherlands suggests, according to a
- Q Biomed Extends its Exclusive Option Agreement With Washington University for Glaucoma Detection Biomarkerhttps://modernod.com/news/q-biomed-extends-its-exclusive-option-agreement-with-washington-university-for-glaucoma-detection-biomarker/2479989/Q BioMed has announced that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and
- US to Develop Drug Import Policy Aimed at Countering Price Hikeshttps://modernod.com/news/us-to-develop-drug-import-policy-aimed-at-countering-price-hikes/2480005/US Health and Human Services Secretary Alex Azar on Thursday directed the FDA to explore how to safely import prescription drug products from other countries “in the event of a dramatic price increase for a drug produced by one manufacturer and not protected by patents or exclusivities.R
- Allergan and Molecular Partners Announce Positive Phase 3 Clinical Trials for Abicipar Pegol for the Treatment of Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-positive-phase-3-clinical-trials-for-abicipar-pegol-for-the-treatment-of-wet-amd/2480008/Allergan and Molecular Partners announced the release of two positive clinical trials, SEQUOIA and CEDAR, for abicipar, demonstrating that both the 8-week and 12-week treatment regimens met the prespecified primary endpoint of noninferiority to ranibizumab. SEQUOIA and CEDAR are identical